ECSP22087539A - Inhibidores de kras tricíclicos fusionados - Google Patents

Inhibidores de kras tricíclicos fusionados

Info

Publication number
ECSP22087539A
ECSP22087539A ECSENADI202287539A ECDI202287539A ECSP22087539A EC SP22087539 A ECSP22087539 A EC SP22087539A EC SENADI202287539 A ECSENADI202287539 A EC SENADI202287539A EC DI202287539 A ECDI202287539 A EC DI202287539A EC SP22087539 A ECSP22087539 A EC SP22087539A
Authority
EC
Ecuador
Prior art keywords
fusioned
tricyclic
compounds
kras inhibitors
kras
Prior art date
Application number
ECSENADI202287539A
Other languages
English (en)
Inventor
Artem Shvartsbart
Chao Qi
Wenyu Zhu
xiaozhao Wang
Wenqing Yao
Rocco Policarpo
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of ECSP22087539A publication Critical patent/ECSP22087539A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Physiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Se describen compuestos de la fórmula I, métodos de uso de compuestos para inhibir la actividad de KRAS y composiciones farmacéuticas que comprenden dichos compuestos. Los compuestos son útiles para tratar, prevenir o mejorar enfermedades o trastornos asociados con la actividad de KRAS, como el cáncer.
ECSENADI202287539A 2020-04-16 2022-11-15 Inhibidores de kras tricíclicos fusionados ECSP22087539A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063011089P 2020-04-16 2020-04-16
US202163146899P 2021-02-08 2021-02-08

Publications (1)

Publication Number Publication Date
ECSP22087539A true ECSP22087539A (es) 2023-01-31

Family

ID=75870725

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202287539A ECSP22087539A (es) 2020-04-16 2022-11-15 Inhibidores de kras tricíclicos fusionados

Country Status (17)

Country Link
US (1) US20210355121A1 (es)
EP (1) EP4135844A1 (es)
JP (2) JP7753246B2 (es)
CN (3) CN121270549A (es)
AU (1) AU2021254794A1 (es)
BR (1) BR112022020841A2 (es)
CA (1) CA3179692A1 (es)
CL (2) CL2022002828A1 (es)
CO (1) CO2022016377A2 (es)
CR (1) CR20220584A (es)
EC (1) ECSP22087539A (es)
IL (1) IL297165A (es)
MX (1) MX2022012780A (es)
PE (1) PE20230825A1 (es)
PH (1) PH12022552739A1 (es)
TW (1) TWI894260B (es)
WO (1) WO2021211864A1 (es)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019217307A1 (en) 2018-05-07 2019-11-14 Mirati Therapeutics, Inc. Kras g12c inhibitors
IL281344B2 (en) 2018-09-10 2025-09-01 Mirati Therapeutics Inc Combination of adagrasib and cetuximab for cancer treatment
EP3849537B1 (en) 2018-09-10 2024-10-23 Mirati Therapeutics, Inc. Combination therapies
JP2022500385A (ja) 2018-09-10 2022-01-04 ミラティ セラピューティクス， インコーポレイテッド 組み合わせ療法
CA3111980A1 (en) 2018-09-10 2020-03-19 Mirati Therapeutics, Inc. Combination therapies
CA3112129A1 (en) 2018-12-05 2020-06-11 Mirati Therapeutics, Inc. Combination therapies
EP3908283A4 (en) 2019-01-10 2022-10-12 Mirati Therapeutics, Inc. KRAS G12C INHIBITORS
AU2020337938B2 (en) 2019-08-29 2025-09-25 Array Biopharma Inc. KRas G12D inhibitors
MX2022003537A (es) 2019-09-24 2022-07-11 Mirati Therapeutics Inc Terapias de combinacion.
EP4067343A4 (en) 2019-11-29 2024-01-03 Taiho Pharmaceutical Co., Ltd. NEW PHENOLIC COMPOUND OR SALT THEREOF
EP4076418A4 (en) 2019-12-20 2024-01-24 Mirati Therapeutics, Inc. Sos1 inhibitors
WO2021150613A1 (en) 2020-01-20 2021-07-29 Incyte Corporation Spiro compounds as inhibitors of kras
US11739102B2 (en) 2020-05-13 2023-08-29 Incyte Corporation Fused pyrimidine compounds as KRAS inhibitors
WO2022047093A1 (en) 2020-08-28 2022-03-03 Incyte Corporation Vinyl imidazole compounds as inhibitors of kras
AU2021340716A1 (en) 2020-09-11 2023-03-30 Mirati Therapeutics, Inc. Crystalline forms of a KRas G12C inhibitor
US12162893B2 (en) 2020-09-23 2024-12-10 Erasca, Inc. Tricyclic pyridones and pyrimidones
US11767320B2 (en) 2020-10-02 2023-09-26 Incyte Corporation Bicyclic dione compounds as inhibitors of KRAS
AU2021401232A1 (en) 2020-12-15 2023-06-22 Mirati Therapeutics, Inc. Azaquinazoline pan-kras inhibitors
US11999753B2 (en) 2020-12-16 2024-06-04 Mirati Therapeutics, Inc. Tetrahydropyridopyrimidine pan-KRas inhibitors
WO2022133345A1 (en) 2020-12-18 2022-06-23 Erasca, Inc. Tricyclic pyridones and pyrimidones
WO2022204112A1 (en) 2021-03-22 2022-09-29 Incyte Corporation Imidazole and triazole kras inhibitors
US12331063B2 (en) 2021-04-29 2025-06-17 Incyte Corporation Hetero-bicyclic inhibitors of KRAS
CR20230558A (es) 2021-05-05 2024-01-24 Revolution Medicines Inc Inhibidores de ras para el tratamiento del cáncer
IL308193A (en) 2021-05-05 2024-01-01 Revolution Medicines Inc RAS inhibitors
CA3224674A1 (en) 2021-07-07 2023-01-12 Pei Gan Tricyclic compounds as inhibitors of kras
CA3229855A1 (en) 2021-08-31 2023-03-09 Incyte Corporation Naphthyridine compounds as inhibitors of kras
US12030883B2 (en) 2021-09-21 2024-07-09 Incyte Corporation Hetero-tricyclic compounds as inhibitors of KRAS
WO2023056421A1 (en) * 2021-10-01 2023-04-06 Incyte Corporation Pyrazoloquinoline kras inhibitors
IL312114A (en) * 2021-10-14 2024-06-01 Incyte Corp Quinoline compounds as Kras inhibitors
AU2022364646B2 (en) * 2021-10-15 2025-10-09 Lomond Therapeutics, Inc. SUBSTITUTED 1H-PYRAZOLO [4,3-c] QUINOLINES, METHODS OF PREPARATION, AND USE THEREOF
JP2024542248A (ja) 2021-11-22 2024-11-13 インサイト・コーポレイション Ｆｇｆｒ阻害剤とｋｒａｓ阻害剤を含む併用療法
JP2025500878A (ja) 2021-12-17 2025-01-15 ジェンザイム・コーポレーション Ｓｈｐ２阻害剤としてのピラゾロピラジン化合物
CN115317490A (zh) * 2021-12-24 2022-11-11 南通大学附属医院 化合物bml-275在制备改善鼻咽癌预后的药物中的应用
CN114394967B (zh) * 2022-01-28 2023-12-15 宁夏农林科学院农业资源与环境研究所（宁夏土壤与植物营养重点实验室） 一种2-吡唑苯胺与1,3-二羰基化合物合成吡唑并喹啉衍生物的方法
EP4227307A1 (en) 2022-02-11 2023-08-16 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
CN119136806A (zh) 2022-03-08 2024-12-13 锐新医药公司 用于治疗免疫难治性肺癌的方法
WO2023240263A1 (en) 2022-06-10 2023-12-14 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2024015731A1 (en) * 2022-07-11 2024-01-18 Incyte Corporation Fused tricyclic compounds as inhibitors of kras g12v mutants
AU2024241633A1 (en) 2023-03-30 2025-11-06 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof
WO2024211663A1 (en) 2023-04-07 2024-10-10 Revolution Medicines, Inc. Condensed macrocyclic compounds as ras inhibitors
PE20260039A1 (es) 2023-04-07 2026-01-09 Revolution Medicines Inc Inhibidores macrociclicos de ras
TW202448897A (zh) 2023-04-14 2024-12-16 美商銳新醫藥公司 Ｒａｓ抑制劑之結晶形式、含有其之組合物及其使用方法
CN121100123A (zh) 2023-04-14 2025-12-09 锐新医药公司 Ras抑制剂的结晶形式
EP4698542A1 (en) * 2023-04-18 2026-02-25 Incyte Corporation 2-azabicyclo[2.2.1]heptane kras inhibitors
WO2024220532A1 (en) * 2023-04-18 2024-10-24 Incyte Corporation Pyrrolidine kras inhibitors
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
TW202500126A (zh) 2023-05-24 2025-01-01 美商金橘生物科技公司 雜環化合物及其用途
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025054530A1 (en) 2023-09-08 2025-03-13 Gilead Sciences, Inc. Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds
WO2025080592A1 (en) * 2023-10-09 2025-04-17 Incyte Corporation Combination comprising a kras g12d inhibitor and an egfr inhibitor for use in the treatment of cancer
TW202530228A (zh) 2023-10-12 2025-08-01 美商銳新醫藥公司 Ｒａｓ抑制劑
TW202535891A (zh) 2023-10-20 2025-09-16 美商默沙東有限責任公司 Ｋｒａｓ蛋白之小分子抑制劑
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
TW202547461A (zh) 2024-05-17 2025-12-16 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
WO2000009495A1 (en) 1998-08-11 2000-02-24 Novartis Ag Isoquinoline derivatives with angiogenesis inhibiting activity
US6133031A (en) 1999-08-19 2000-10-17 Isis Pharmaceuticals Inc. Antisense inhibition of focal adhesion kinase expression
GB9905075D0 (en) 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
DE60105023T2 (de) 2000-06-28 2005-08-18 Smithkline Beecham P.L.C., Brentford Nassvermahlungsverfahren
MXPA04002243A (es) 2001-09-19 2004-06-29 Aventis Pharma Sa Compuestos quimicos.
CN101703509A (zh) 2001-10-30 2010-05-12 诺瓦提斯公司 作为flt3受体酪氨酸激酶活性抑制剂的星形孢菌素衍生物
CA2466279A1 (en) 2001-11-13 2003-05-22 Dana-Farber Cancer Institute, Inc. Agents that modulate immune cell activation and methods of use thereof
DE60303009T2 (de) 2002-01-22 2006-07-13 Warner-Lambert Co. Llc 2-(pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-one
AR037647A1 (es) 2002-05-29 2004-12-01 Novartis Ag Derivados de diarilurea utiles para el tratamiento de enfermedades dependientes de la cinasa de proteina
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
TWI335913B (en) 2002-11-15 2011-01-11 Vertex Pharma Diaminotriazoles useful as inhibitors of protein kinases
UA80767C2 (en) 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
CN1753912B (zh) 2002-12-23 2011-11-02 惠氏公司 抗pd-1抗体及其用途
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
AR045944A1 (es) 2003-09-24 2005-11-16 Novartis Ag Derivados de isoquinolina 1.4-disustituidas
BRPI0517887A (pt) 2004-11-24 2008-10-21 Novartis Ag combinações de inibidores de jaks
ES2720160T3 (es) 2005-05-09 2019-07-18 Ono Pharmaceutical Co Anticuerpos monoclonales humanos contra muerte programada 1(PD-1) y métodos para tratar el cáncer usando anticuerpos dirigidos contra PD-1 solos o junto con otras sustancias inmunoterapéuticas
EA019344B1 (ru) 2005-07-01 2014-03-31 МЕДАРЕКС, Эл.Эл.Си. Человеческие моноклональные антитела против лиганда-1 запрограммированной гибели клеток (pd-l1) и их применения
JP5191537B2 (ja) 2007-06-18 2013-05-08 エム・エス・ディー・オス・ベー・フェー ヒトのプログラムされたデスレセプターｐｄ−１に対する抗体
WO2009085185A1 (en) 2007-12-19 2009-07-09 Amgen Inc. Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
BRPI0919377A2 (pt) 2008-09-26 2016-09-27 Dana Farber Cancer Inst Inc anticorpo isolado ou um fragmento ligante de antígeno do memso, ácido nucleico isolado, vetor, célula hospedeira, composição farmacêutica, método de produzir o referido anticorpo ou fragmento, uso dos mesmos, e composição compreendendo o referido anticorpo ou fragmento
HUE065752T2 (hu) 2008-12-09 2024-06-28 Hoffmann La Roche Anti-PD-L1 antitestek és felhasználásuk T-sejt funkció elõsegítésére
PA8852901A1 (es) 2008-12-22 2010-07-27 Lilly Co Eli Inhibidores de proteina cinasa
ES2629337T3 (es) 2009-02-09 2017-08-08 Inserm - Institut National De La Santé Et De La Recherche Médicale Anticuerpos contra PD-1 y anticuerpos contra PD-L1 y usos de los mismos
GB0919423D0 (en) * 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
EP2504028A4 (en) 2009-11-24 2014-04-09 Amplimmune Inc SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
US20130022629A1 (en) 2010-01-04 2013-01-24 Sharpe Arlene H Modulators of Immunoinhibitory Receptor PD-1, and Methods of Use Thereof
UY33227A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
WO2011159877A2 (en) 2010-06-18 2011-12-22 The Brigham And Women's Hospital, Inc. Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
MX379532B (es) 2010-10-25 2025-03-10 G1 Therapeutics Inc Inhibidores de cdk.
CN102655637A (zh) * 2011-03-01 2012-09-05 中兴通讯股份有限公司 一种移动通信系统和组网方法
PT2688887E (pt) 2011-03-23 2015-07-06 Amgen Inc Inibidores duais tricíclicos fusionados de cdk 4/6 e flt3
EP2769980B1 (en) * 2011-10-07 2016-02-03 Eisai R&D Management Co., Ltd. Pyrazoloquinoline derivative as pde9 inhibitors
AU2016244017B2 (en) * 2015-04-03 2020-07-23 Nant Holdings Ip, Llc Compositions and methods of targeting mutant K-ras
WO2016199943A1 (en) * 2015-06-11 2016-12-15 Takeda Pharmaceutical Company Limited Heterocyclic compounds
HUE055207T2 (hu) 2015-07-30 2021-11-29 Macrogenics Inc PD-1 és LAG-3 kötõ molekulák és eljárások azok alkalmazására
US20170107216A1 (en) 2015-10-19 2017-04-20 Incyte Corporation Heterocyclic compounds as immunomodulators
US10414757B2 (en) * 2015-11-16 2019-09-17 Araxes Pharma Llc 2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof
AU2016358100B2 (en) 2015-11-19 2021-05-27 Incyte Corporation Heterocyclic compounds as immunomodulators
TW201726623A (zh) 2015-12-17 2017-08-01 英塞特公司 作為免疫調節劑之雜環化合物
TWI850624B (zh) 2015-12-22 2024-08-01 美商英塞特公司 作為免疫調節劑之雜環化合物
TW201808950A (zh) 2016-05-06 2018-03-16 英塞特公司 作為免疫調節劑之雜環化合物
US20170342060A1 (en) 2016-05-26 2017-11-30 Incyte Corporation Heterocyclic compounds as immunomodulators
DK3472167T3 (da) 2016-06-20 2022-09-05 Incyte Corp Heterocykliske forbindelser som immunomodulatorer
EP3484866B1 (en) 2016-07-14 2022-09-07 Incyte Corporation Heterocyclic compounds as immunomodulators
EP3504198B1 (en) 2016-08-29 2023-01-25 Incyte Corporation Heterocyclic compounds as immunomodulators
IL295660A (en) 2016-12-22 2022-10-01 Incyte Corp Benzooxazole derivatives as immunomodulators
ES2874756T3 (es) 2016-12-22 2021-11-05 Incyte Corp Derivados de triazolo[1,5-A]piridina como inmunomoduladores
EP3558963B1 (en) 2016-12-22 2022-03-23 Incyte Corporation Bicyclic heteroaromatic compounds as immunomodulators
WO2018119263A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds derivatives as pd-l1 internalization inducers
EP3558973B1 (en) 2016-12-22 2021-09-15 Incyte Corporation Pyridine derivatives as immunomodulators
ES2929193T3 (es) 2016-12-22 2022-11-25 Incyte Corp Derivados de tetrahidro imidazo[4,5-c]piridina como inductores de la internalización de PD-L1
RS64055B1 (sr) 2018-03-30 2023-04-28 Incyte Corp Heterociklična jedinjenja kao imunomodulatori
JP7351850B2 (ja) * 2018-04-25 2023-09-27 イネイト・テューマー・イミュニティ・インコーポレイテッド Ｎｌｒｐ３修飾因子
EP4219492B1 (en) 2018-05-11 2024-11-27 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2020037091A1 (en) * 2018-08-16 2020-02-20 Innate Tumor Immunity, Inc. Imidazo[4,5-c]quinoline derived nlrp3-modulators

Also Published As

Publication number Publication date
JP2023522202A (ja) 2023-05-29
CL2023002090A1 (es) 2023-12-15
PH12022552739A1 (en) 2024-03-25
CA3179692A1 (en) 2021-10-21
TW202204355A (zh) 2022-02-01
WO2021211864A1 (en) 2021-10-21
CO2022016377A2 (es) 2023-02-27
TWI894260B (zh) 2025-08-21
CN121270549A (zh) 2026-01-06
MX2022012780A (es) 2023-01-18
CN121270550A (zh) 2026-01-06
US20210355121A1 (en) 2021-11-18
BR112022020841A2 (pt) 2023-05-02
EP4135844A1 (en) 2023-02-22
CL2022002828A1 (es) 2023-03-31
CR20220584A (es) 2023-02-15
AU2021254794A1 (en) 2022-12-15
JP2026021310A (ja) 2026-02-10
CN115702025B (zh) 2025-09-12
IL297165A (en) 2022-12-01
JP7753246B2 (ja) 2025-10-14
CN115702025A (zh) 2023-02-14
PE20230825A1 (es) 2023-05-19

Similar Documents

Publication Publication Date Title
ECSP22087539A (es) Inhibidores de kras tricíclicos fusionados
CO2024001285A2 (es) Compuestos tricíclicos como inhibidores de kras
ECSP24035717A (es) Compuestos de quinolina como inhibidores de kras
DOP2025000264A (es) Inhibidores de kras de 2-azabiciclo [2.2.1] heptano
CL2020002146A1 (es) Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el cáncer.
MX2025000271A (es) Inhibidores de kras de anillo fusionado para el tratamiento de enfermedades
MX2019002750A (es) Derivados de pirazolopiridina como moduladores de cinasa 1 progenitora hematopoyetica (hpk1) y usos de los mismos para tratamiento de cancer.
CL2021001656A1 (es) Compuestos de imidazopiridina e imidazopiridina y sus usos.
CL2024003450A1 (es) Compuestos y usos de estos
CL2023002223A1 (es) Inhibidores de cdk2 y métodos de uso de los mismos
CL2023002633A1 (es) Derivados de uracilo como inhibidores de trpa1
MX2025009815A (es) Inhibidores de la integrina alfa4beta7 macrociclica
UY39865A (es) Pirazin-2-carboxamidas sustituidas como inhibidores de hpk1 para el tratamiento del cáncer
CL2023003921A1 (es) Inhibidores de transglutaminasas
CO2025016647A2 (es) Inhibidores de egfr para el tratamiento de enfermedades
MX2024008413A (es) Compuestos macrocíclicos y uso como inhibidores de cinasas.
CO2022017969A2 (es) Compuestos de imidazopiridazina con actividad como inhibidores de alk2
ECSP24007534A (es) Inhibidores de transglutaminasas
CL2023003979A1 (es) Inhibidores de las transglutaminasas
AR126389A1 (es) Compuestos tricíclicos como inhibidores de kras
AR132459A1 (es) Inhibidores de kras de pirrolidina
AR117459A1 (es) Imidazopiridina y compuestos de imidazopiridazina y usos de los mismos
DOP2025000274A (es) Inhibidores de egfr para el tratamiento de enfermedades
AR134259A1 (es) Compuestos de pirimidina bicíclicos, métodos y usos de estos
MX2023007297A (es) 3-fluoro-but-3-enamidas ramificadas macrociclicas como inhibidores de mcl-1.